CAMBRIDGE, Mass., Sept. 03, 2020 (GLOBE NEWSWIRE) — Cue Biopharma, Inc. (NASDAQ: CUE), a clinical-stage biopharmaceutical company engineering a novel class of injectable biologics to selectively engage and modulate targeted T cells within the body, announced today it will present at the Baird Global Healthcare Conference on Wednesday, September 9, 2020, the Morgan Stanley Global Healthcare Conference on Thursday, September 17, 2020 and the Oppenheimer & Co. Fall Healthcare Life Sciences and MedTech Summit on Wednesday, September 23, 2020. The Company will also participate in Citi’s 15th Annual BioPharma Virtual Conference on September 9-10, 2020.
Cue Biopharma will provide an overview highlighting the Immuno-STAT™ (Selective Targeting and Alteration of T cells) platform and its next-generation Neo-STAT™. The presentations will also include an update on the company’s expanding pipeline and continued progress on the IL-2 based CUE-100 series with an emphasis on CUE-101, its lead clinical candidate for HPV16-driven head and neck cancer.Additional presentation details can be found below:Baird Global Healthcare Conference
Date and Time: Wednesday, September 9, 2020 at 2:00 p.m. EDT
Location: Virtual
A live webcast of the presentation will be available for attendees only.Citi’s 15th Annual BioPharma Virtual Conference
Date: September 9-10, 2020
Location: Boston/VirtualMorgan Stanley Global Healthcare Conference
Date and Time: Thursday, September 17, 2020 at 5:00 p.m. EDT
Location: Virtual
A live and archived webcast of the presentation will be available in the Investors section of the Company’s website at www.cuebiopharma.com.Oppenheimer & Co. Fall Healthcare Life Sciences and MedTech Summit
Date and Time: Wednesday, September 23, 2020 at 9:10 a.m. EDT
Location: New York/Virtual
A live webcast of the presentation will be available for attendees only.About Cue Biopharma
Cue Biopharma, a clinical-stage biopharmaceutical company, is engineering a novel class of injectable biologics to selectively engage and modulate targeted T cells within the body to transform the treatment of cancer, infectious diseases and autoimmune diseases. The company’s proprietary platform, Immuno-STAT™ (Selective Targeting and Alteration of T cells) is designed to harness the body’s intrinsic immune system without the need for ex vivo manipulation.Headquartered in Cambridge, Massachusetts, we are led by an experienced management team and independent Board of Directors with deep expertise in the design and clinical development of protein biologics, immunology and immuno-oncology.For more information, visit www.cuebiopharma.com and follow us on Twitter https://twitter.com/CueBiopharma.Forward-Looking Statements
This press release contains “forward-looking statements” within the meaning of Section 27A of the Securities Act of 1933, as amended, and Section 21E of the Securities Exchange Act of 1934, as amended, that are intended to be covered by the “safe harbor” created by those sections. Forward-looking statements, which are based on certain assumptions and describe our future plans, strategies and expectations, can generally be identified by the use of forward-looking terms such as “believe,” “expect,” “may,” “will,” “should,” “would,” “could,” “seek,” “intend,” “plan,” “goal,” “project,” “estimate,” “anticipate,” “strategy,” “future,” “likely” or other comparable terms. All statements other than statements of historical facts included in this press release regarding our strategies, prospects, financial condition, operations, costs, plans and objectives are forward-looking statements. Examples of forward-looking statements include, among others, statements we make regarding anticipated results of our drug development efforts, including study results, and our expectations regarding regulatory developments and expected future operating results. Forward-looking statements are neither historical facts nor assurances of future performance. Instead, they are based only on our current beliefs, expectations and assumptions regarding the future of our business, future plans and strategies, projections, anticipated events and trends, the economy and other future conditions. Because forward-looking statements relate to the future, they are subject to inherent uncertainties, risks and changes in circumstances that are difficult to predict and many of which are outside of our control. Our actual results and financial condition may differ materially from those indicated in the forward-looking statements. Therefore, you should not rely on any of these forward-looking statements. Important factors that could cause our actual results and financial condition to differ materially from those indicated in the forward-looking statements include, among others, our limited operating history, limited cash and a history of losses; our ability to achieve profitability; potential setbacks in our research and development efforts including negative or inconclusive results from our preclinical studies, our ability to secure required U.S. Food and Drug Administration (“FDA”) or other governmental approvals for our product candidates and the breadth of any approved indication; adverse effects caused by public health pandemics, including COVID-19, including possible effects on our operations and clinical trials; negative or inconclusive results from our clinical studies or serious and unexpected drug-related side effects or other safety issues experienced by participants in our clinical trials; delays and changes in regulatory requirements, policy and guidelines including potential delays in submitting required regulatory applications to the FDA; our reliance on licensors, collaborators, contract research organizations, suppliers and other business partners; our ability to obtain adequate financing to fund our business operations in the future; ; and the other risks and uncertainties described in the Risk Factors and in Management’s Discussion and Analysis of Financial Condition and Results of Operations sections of our most recently filed Annual Report on Form 10-K and any subsequently filed Quarterly Report(s) on Form 10-Q. Any forward-looking statement made by us in this press release is based only on information currently available to us and speaks only as of the date on which it is made. We undertake no obligation to publicly update any forward-looking statement, whether written or oral, that may be made from time to time, whether as a result of new information, future developments or otherwise.Investor Contact
George B. Zavoico, Ph.D.
VP, Investor Relations & Corporate Development
Cue Biopharma, Inc.
[email protected]Media Contact
Alison Chen
LifeSci Communications
[email protected]
Bay Street News
